Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus

Background and Aims Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated t...

Full description

Saved in:
Bibliographic Details
Published inLiver international Vol. 39; no. 5; pp. 967 - 975
Main Authors Hegade, Vinod S., Pechlivanis, Alexandros, McDonald, Julie A. K., Rees, Douglas, Corrigan, Margaret, Hirschfield, Gideon M., Taylor‐Robinson, Simon D., Holmes, Elaine, Marchesi, Julian R., Kendrick, Stuart, Jones, David E.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.05.2019
Subjects
Online AccessGet full text
ISSN1478-3223
1478-3231
1478-3231
DOI10.1111/liv.14069

Cover

More Information
Summary:Background and Aims Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor. Methods We studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC‐MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing. Results In PBC patients with pruritus, serum levels of total and glyco‐conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro‐ and glyco‐conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro‐ and glyco‐ conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04). Conclusions Pruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition.
Bibliography:Funding information
This study was funded via the research grant from the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre. BAT117213 sample collection was funded by GlaxoSmithKline (GSK). This paper presents independent research and the views expressed are those of the authors and not necessarily those of the NIHR or GSK.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1478-3223
1478-3231
1478-3231
DOI:10.1111/liv.14069